Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.59 |
| ▸ | CNR1 | P21554 | 4/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333370 | 0.90 | CNR2 (0.66) | CNR2CNR1HTR4CYP3A4CYP2D6 | |
| SCHEMBL4320118 | 0.86 | CNR2 (0.60) | CNR2CNR1HTR4CYP3A4CYP2D6 | |
| SCHEMBL4325229 | 0.84 | CNR2 (0.51) | CNR2CNR1 | |
| SCHEMBL4318734 | 0.83 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL4327406 | 0.83 | CNR2 (0.66) | CNR2CNR1HTR4CYP3A4CYP2D6 | |
| SCHEMBL13578108 | 0.81 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL4319969 | 0.81 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL13578348 | 0.81 | CNR2 (0.73) | CNR2CNR1CYP3A4 | |
| SCHEMBL13578251 | 0.80 | CNR2 (0.46) | CNR2CNR1HTR4CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4324531 | 0.79 | CNR2 (0.70) | CNR2CNR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885HTR4 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.